P-glycoprotein (Pgp)-related multidrug resistance (MDR) is frequently observed in acute non-lymphocytic leukemia (ANLL) and is associated with a poor response to standard chemotherapy. Cyclosporin A (CsA) is an effective downmodulator of Pgp-related MDR in vitro and has already been tested for that purpose in vivo also. Since Pgp is expressed in several normal cells and tissues, the modulation of Pgp can also modify total body exposure to antileukemic drugs and can alter and increase the toxicity of the antileukemic treatment. We report here the results of a study where 46 consecutive adult patients with ANLL were assigned to receive the same standard chemotherapy regimen of arabinosyl cytosine and idarubicin (IDA) for remission induction or consolidation, without or with CsA. Twenty-eight patients received 36 courses of chemotherapy without CsA and 18 patients received 32 courses of chemotherapy with CsA. CsA dose was 10-12.5 mg/kg/day and was given as a continuous i.v. infusion for 72 h. Whole blood CsA steady-state concentration ranged between 0.61 and 1.14 M. The IDA area-under-the-curve was about twice as high in the cases that received CsA than in the other cases. CsA had no detectable effects on renal function and fluid balance, but significantly increased systemic blood diastolic pressure and conjugated bilirubine concentration. Furthermore, CsA-treated patients had greater, and more severe, oral and intestinal mucosal toxicity, with more severe adverse events, including more cases of gram-negative bacteremia, and with a delayed hemopoietic recovery. In conclusion, this study showed that an attempt at an effective downmodulation of Pgp-mediated MDR would substantially increase the hemopoietic and mucosal toxicity of antileukemic treatment and that the increase is accounted for, at least in part, by an increase of total body exposure to IDA.
Introduction
The sensitivity of tumor cells to antitumor agents is the major determinant of response to cancer chemotherapy. One important factor of multidrug resistance (MDR) is the overexpression of a 170 kDa glycoprotein, also known as P-glycoprotein or Pgp 1,2 that enhances the extrusion from the cells of a number of non-polar hydrophobic compounds, including the anthracyclines, that are first-line drugs for the treatment of acute leukemia. Therefore, it is not surprising that several independent studies of acute nonlymphocytic leukemia (ANLL) showed a negative relationship between Pgp expression and response to treatment. [3] [4] [5] [6] [7] [8] [9] [10] [11] Idarubicine (IDA) is a 4-demethoxy derivative of daunorubicin, is more active than daunorubicin against MDR cells in vitro 12, 14 and is slightly more active than the parent compound in the treatment of ANLL. [15] [16] [17] We found that in vitro the sensitivity of MDR cells to IDA could be fully restored and reverted to the sensitivity of non-MDR cells, by combining IDA with Correspondence: M Baccarani, Division of Hematology, University Hospital, 33100 Udine, Italy; Fax: 39 432 559661 Received 13 January 1998; accepted 21 March 1998 CsA 1-2 m. 13, 14 Based on these findings, we planned a clinical study with the purpose of testing a standard chemotherapy regimen of arabinosyl cytosine (AC) and of the most effective anthracycline derivative, namely IDA, in combination with CsA, for the treatment of ANLL. Since the combination could predictably lead to an increase of toxicity, related to the Pgp content and function in normal tissues, the first purpose of this study was to assess the feasibility, side-effects and toxicity of the combination, by comparison with the same standard regimen of AC and IDA without CsA.
Patients and methods
The study was performed in 46 consecutive eligible patients who were admitted for treatment of ANLL and were assigned to the same chemotherapy regimen. Five patients denied consent for adjuvant treatment with CsA, so that 18 patients were actually treated with CsA and 28 did not receive CsA (Table  1 ). The median age was 55 and 56 years, respectively. The distribution according to the morphologic FAB classification and the number of the courses of chemotherapy that were evaluated is shown in Table 1 . There were 36 courses of chemotherapy without CsA and 32 courses with CsA. The number of courses exceeded the number of patients, because several patients were evaluated more than once, for remission 2 twice a day as a 2-h i.v. infusion for a total of six doses, and three doses of IDA as in the first course. CsA was administered as a 72-h continuous i.v. infusion that was started 12 h before the first IDA dose and was terminated 12 h after the third IDA dose. CsA dose was 10 mg/kg/24 h in 23 courses, 12.5 mg/kg/24 h in seven courses and 15 mg/kg/24 h in two courses. In the patients who achieved a remission no subsequent chemotherapy was given. They were treated with autologous or allogeneic bone marrow transplantation, whenever eligible for the procedure.
Toxicity and side-effects were recorded daily using WHO definitions and grading. All patients were nursed in two-bed non-isolated rooms. A central venous catheter was placed in all cases. Platelets (as apheresis from single donors) were transfused daily in case of hemorrhage or three times a week in case of platelet count less than 20 × 10 9 /l without hemorrhage. Ciprofloxacin (1 g/day orally) and itraconazole (200 mg/day orally) were given prophylactically. Blood cultures were taken in triplicate at any temperature spike over 38°C. Antibiotics were given i.v. in cases of documented infection or fever (body temperature Ͼ38°C for more than 24 h). Antifungals (Amphotericin-B) were given i.v. in case of no response to antibiotics i.v. for more than 6 days.
Pgp expression was evaluated in fixed and permeabilized blast cells using an indirect flow cytometry technique and a specific anti-Pgp monoclonal antibody (MRK-16), as previously described. 18 Plasma IDA concentration was determined by high-performance liquid chromatography with a fluorescence detector according to the method of Camaggi et al 19 with few modifications. CsA whole blood concentration was measured with a fluorescence polarization immunoassay. Reagents for this monoclonal antibody-based assay were obtained from Abbot Laboratories Diagnostic Division (Chicago, IL, USA) and analyses were carried out on a Tdx Analyser according to the company's application notes. The Student's t-test and the 2 test were used whenever appropriate. P values were two-sided. Table 2 shows treatment effect on serum creatinine concentration (no effect, no difference between AC + IDA and AC + IDA + CsA, no cases of renal failure), body weight (slight increase, but no difference), systemic blood pressure (diastolic values were significantly higher in CsA-treated cases), serum bilirubine concentration (that became significantly higher in CsA-treated patients than in controls) and AST/ALT (no difference). The increase of bilirubin was completely accounted for by conjugated bilirubine. Table 3 lists oral and gastrointestinal toxicity. In the CsA group there were more cases with grades 1-2 vomiting (69 vs 36%, P = 0.01), more cases with grades 3-4 oral mucositis (22 vs 3%, P = 0.03), and there were four cases (12%) of severe (grades 3-4), acute, necrotizing and hemorrhagic enteritis. The number of cases who became febrile was the same in controls and in CsA-treated cases (Table 4) , but in the CsA group the number of days with fever was slightly higher, whereas the total number of days with antibiotics i.v. was significantly higher. The number of cases with Gram-positive bacteremia was not different, but the number of cases with Gram-negative bacteremia was higher in the CsA group (34 vs 11%, P = 0.01). Herpes simplex oral mucositis developed in 11/32 (34%) CsA-treated patients and 1/36 (3%) controls (P = 0.002). Table 5 shows that in the CsA-treated group the hematologic recovery was slightly delayed, the number of platelet and red cell transfusions was higher, and the time to hospital discharge was significantly longer (29 ± 9 days vs 23 ± 6 days, P = 0.001).
Results
The steady-state whole blood CsA concentration ranged between 0.61 M and 1.44 M, with a median value of 0.86 in the 23 courses where CsA was administered at a dose of 10 mg/kg/day and of 1.15 in the seven courses where CsA dose was 12.5 mg/kg/day. These concentrations were maintained for 72 h. IDA plasma concentration was measured in 11 patients who did not receive CsA and in nine patients who were treated with CsA. t 1/2␣ was 0.34 ± 0.26 h in the former and 0.38 ± 0.42 in the latter. t 1/2␤ was 9.9 ± 6 h and 12.4 ± 5.2 h, respectively. The area under the curve (g/l.h) of IDA was 315 ± 158 in the controls and 558 ± 197 in the CsA group (P = 0.01).
The short-term outcome of the treatment is reported in Table 6 . Among the patients who were treated at diagnosis, remissions were 7/13 without CsA and 8/12 with CsA, and there were two cases of DDI in the CsA group. Among the patients who were treated in relapse, remissions were 4/13 without CsA and 7/10 with CsA. Remission duration was not evaluable because post-remission treatment varied from nothing to allogeneic bone marrow transplantation.
Discussion
When this study was planned, we knew that in ANLL Pgp overexpression was associated with an unfavorable outcome, that IDA was more active than DNR against MDR leukemic cells, and that in vitro it was possible to neutralize with CsA Pgp-related MDR to IDA. We hoped that adjuvant treatment with CsA could be more effective, but we were afraid of toxicity against normal cells, especially in the particular clinical setting of ANLL, where the toxic effects of chemotherapy are associated with leukemia-related myelosuppression.
There are few studies of the toxicity of cancer chemotherapy with CsA, [20] [21] [22] [23] [24] [25] and only two reports described the effects of the administration of CsA for remission induction in ANLL. List et al 22 The present study, where CsA was given in combination Acute, necrotizing, hemorrhagic, neutropenic enterocolitis. Oral and gastrointestinal (GI) toxicity was probably due to the combination of CsA with antileukemic treatment, with a possible exception for oral mucositis (see Table 4 ). In the CsA group there were four cases of severe necrotizing, hemorrhagic enterocolitis, that required surgery in one case and that was fatal in one case. NS, P Ͼ 10. Body temperature у38°C for у24 h. In the patients who received CsA the number of days with fever, the number of days with antibiotic treatment and the number of cases with Gram-negative bacteremia was higher than in the controls, suggesting that CsA potentiated the hemopoietic and the GI mucosal toxicity of antileukemic treatment. In contrast, the remarkable increase of herpetic oral mucositis could be due to an acute immunosuppressive effect of CsA alone.
with the most effective and the most toxic anthracycline for the treatment of ANLL, showed that a 3-day infusion of CsA at a dose of 10 mg/kg/day was well tolerated, had a small effect on systemic blood pressure, did not influence renal and cardiac function and had no neurologic side-effects. Conjugated hyperbilirubinemia was the only substantial side-effect. However, the toxic effects of chemotherapy on hematopoiesis and on intestinal mucosa were significantly enhanced, leading to more and more severe clinical complications. The higher frequency of Gram-negative bacteremia was probably a The hematologic recovery was slightly delayed in CsA-treated patients, and more platelet and red cell transfusions were required. The time to discharge was also significantly longer. NS, P Ͼ 0.10. G-CSF, granulocyte-colony stimulating factor. consequence of a major disruption of the GI mucosal barrier, while oral mucositis could be more frequent and more severe also because of herpes simplex reactivation, possibly related to the immunosuppressive activity of CsA. There are two main reasons for the observed increase in chemotherapy toxicity. The first is that because hemopoietic progenitors 26, 27 and GI epithelial cells [28] [29] [30] overexpress Pgp constitutively, an effective Pgp downmodulation increases the sensitivity of these normal cells to IDA. The second is that the coadministration of CsA increases total body exposure to IDA. Therefore, an effective MDR modifier such as CsA is likely to increase treatment toxicity (and maybe also treatment efficacy) by allowing normal and tumor cells to be exposed to higher drug concentrations and for a longer period of time, irrespective of any possible cell-specific effects.
It is not yet easy to assess the expression of MDR in leukemia and to evaluate the effect of MDR on treatment results 31, 32 and CsA is only a prototype or a progenitor of a class of MDR modifiers. Among several less immunosuppressive Cs derivatives, PSC 833 was found to be more powerful than CsA in vitro 13, 14, 33 and is currently being tested in a number of clinical trials. This report should warn of the clinical problems that can be expected when adjuvant chemotherapy with MDR modifiers is employed in the specific clinical setting of the treatment of ANLL, namely an increase of hematologic and mucosal toxicity, leading to more frequent and more severe adverse events, especially infection and enteritis. Substituting CsA with PSC 833 or other agents could avoid some direct CsA side-effects, such as hypertension, hyperbilirubinemia and immunosuppression, but if PSC 833 or other agents proved to be powerful downmodulators of MDR in vivo also, toxicity as high as or higher than that we observed with CsA, is expected. Toxicity would probably be reduced by decreasing the dose of chemotherapy, but that would also decrease the response rate. In this study, carried out between 1993 and 1996, we evaluated Pgp expression with only one monoclonal antibody (MRK-16), while it is now agreed that one reagent and one method may not be sufficient to define the level of MDR. 31, 32 The remission rate of the cases that were MRK-16 positive and received CsA was encouraging (8/12 at diagnosis and 7/10 in relapse). However, the cost was high and prospective randomized studies are required to evaluate if effective MDR downmodulation would actually increase the response rate, prolong response duration, and be cost-effective.
